Puma Biotechnology (PBYI) Announces Presentation Of Positive PB272 Phase II Data At The 2014 ASCO Annual Meeting
6/2/2014 9:17:15 AM
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the treatment of HER2 positive metastatic breast cancer that has metastasized to the brain. The data was presented today in a poster presentation at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by